CAMBRIDGE, Mass. March 9, 2022 – Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNAᵀᴹ), today announced the appointment of Thomas Ebeling to the Board of Directors and William Shen, Ph.D., as Chief Business Officer.